Inadequate response to targeted immunomodulators for rheumatoid arthritis may lead to significantly higher economic burden, including higher health care resource utilization. READ MORE
A recent study summarized the available evidence on adverse events associated with checkpoint inhibitors in patients with cancer and preexisting autoimmune disease.
Higher scores on a multi-biomarker disease activity system are associated with hospital infection, myocardial infarction, and coronary heart disease events in older patients with rheumatoid arthritis.
A myriad of factors including lack of guidelines, wealth of drug options, cost concerns, and varying efficacy make treatment decisions for rheumatoid arthritis a challenge.
Research in Review
An analysis of biologics for rheumatoid arthritis showed tocilizumab monotherapy and tocilizumab plus methotrexate were superior to conventional drugs.
Patients with RA previously treated to a first-line TNF drug may experience a better outcome with a non-TNF biologic agent than with a second anti-TNF therapy.
The presence of two cellular biomarkers may help to identify patients with rheumatoid arthritis who will not benefit from rituximab.
There may be little difference between treatment strategies that utilize musculoskeletal ultrasound or disease activity in rheumatoid arthritis measurements.